- Home
- ERAS vs EU Comparison
ERAS vs EU Comparison
Compare ERAS & EU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- EU
- Stock Information
- Founded
- ERAS 2018
- EU 2009
- Country
- ERAS United States
- EU United States
- Employees
- ERAS N/A
- EU N/A
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- EU Other Metals and Minerals
- Sector
- ERAS Health Care
- EU Basic Materials
- Exchange
- ERAS Nasdaq
- EU Nasdaq
- Market Cap
- ERAS 723.8M
- EU 652.4M
- IPO Year
- ERAS 2021
- EU N/A
- Fundamental
- Price
- ERAS $1.90
- EU $3.48
- Analyst Decision
- ERAS Strong Buy
- EU Strong Buy
- Analyst Count
- ERAS 5
- EU 2
- Target Price
- ERAS $5.70
- EU $6.50
- AVG Volume (30 Days)
- ERAS 1.5M
- EU 1.4M
- Earning Date
- ERAS 11-12-2024
- EU 11-14-2024
- Dividend Yield
- ERAS N/A
- EU N/A
- EPS Growth
- ERAS N/A
- EU N/A
- EPS
- ERAS N/A
- EU N/A
- Revenue
- ERAS N/A
- EU $44,972,063.00
- Revenue This Year
- ERAS N/A
- EU N/A
- Revenue Next Year
- ERAS N/A
- EU $55.73
- P/E Ratio
- ERAS N/A
- EU N/A
- Revenue Growth
- ERAS N/A
- EU N/A
- 52 Week Low
- ERAS $1.64
- EU $3.02
- 52 Week High
- ERAS $3.45
- EU $5.05
- Technical
- Relative Strength Index (RSI)
- ERAS 29.70
- EU 51.32
- Support Level
- ERAS $1.77
- EU $3.26
- Resistance Level
- ERAS $2.84
- EU $3.46
- Average True Range (ATR)
- ERAS 0.18
- EU 0.18
- MACD
- ERAS -0.07
- EU 0.00
- Stochastic Oscillator
- ERAS 12.15
- EU 40.68
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About EU enCore Energy Corp.
enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's material properties and projects are the Rosita Project located in Texas, the Alta Mesa Uranium project in Texas, the Crownpoint and Hosta Butte Uranium Project located in New Mexico, the Dewey Burdock Project located in South Dakota, and the Gas Hills Project located in Wyoming.